4.7 Review

Nrf2-ARE pathway: An emerging target against oxidative stress and neuroinflammation in neurodegenerative diseases

Journal

PHARMACOLOGY & THERAPEUTICS
Volume 157, Issue -, Pages 84-104

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pharmthera.2015.11.003

Keywords

Neurodegenerative diseases; Oxidative stress; Neuroinflammation; Nuclear factor E2-related factor 2 Nrf2; Electrophile response elements; Phase II antioxidant response; Nrf2-inducers

Funding

  1. European Commission - ERC, People (Marie Curie Actions) FP7 under REA grant agreement [PCIG11-GA-2012-322156]
  2. Spanish Ministry of Health (Instituto de Salud Carlos III) [PI14/00372]
  3. Miguel Servet [CP11/00165, CP14/00008]
  4. MECD [AP2010-1219, FPU13/03737]
  5. UAM
  6. Fundacion Teofilo Hernando

Ask authors/readers for more resources

Neurodegenerative diseases (NDDs) are predicted to be the biggest health concern in this century and the second leading cause of death by 2050. The main risk factor of these diseases is aging, and as the aging population in Western societies is increasing, the prevalence of these diseases is augmenting exponentially. Despite the great efforts to find a cure, current treatments remain ineffective or have low efficacy. Increasing lines of evidence point to exacerbated oxidative stress, mitochondrial dysfunction and chronic neuroinflammation as common pathological mechanisms underlying neurodegeneration. We will address the role of the nuclear factor E2-related factor 2 (Nrf2) as a potential target for the treatment of NDDs. The Nrf2-ARE pathway is an intrinsic mechanism of defence against oxidative stress. Nrf2 is a transcription factor that induces the expression of a great number of cytoprotective and detoxificant genes. There are many evidences that highlight the protective role of the Nrf2-ARE pathway in neurodegenerative conditions, as it reduces oxidative stress and neuroinflammation. Therefore, the Nrf2 pathway is being increasingly considered a therapeutic target for NDDs. Herein we will review the deregulation of the Nrf2 pathway in different NDDs and the recent studies with Nrf2 inducers as proof-of-concept for the treatment of those devastating pathologies. (C) 2015 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available